Background: Ustekinumab(UST) has been shown to induce and maintain clinical response and remission in Crohn's disease (CD) in two induction [(UNITI-1 (anti-TNF failures) and UNITI-2 (conventional therapy failures)] and 1 maintenance (IM-UNITI) randomised, PBO-controlled Phase 3 trials. The use of a more stringent composite outcome of clinical response and a ≥50% reduction from baseline(BL) in either fecal calprotectin(FeCa) or CRP concentration has been shown to decrease PBO rate and facilitate assessment of meaningful treatment effect.
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Despite surveillance and increased use of biologics and immunosuppressives colorectal cancer detection in IBD patients remains unchanged over the past ten years Background: Crohn's disease (CD) developing during childhood and adolescence encompasses a spectrum of phenotypes and disease severity. Risk stratification to facilitate early, more individualised therapy is key to optimizing outcomes. We aimed to systematically review the evidence pertaining to prediction of chronically active inflammatory activity and disease complications in paediatric CD. Methods: We searched Pubmed and EMBASE from 1992 to 2017 for observational or controlled, English language studies reporting longitudinal associations between patient/disease characteristics and chronically active inflammatory disease or the following CD complications: B2/B3/perianal disease, linear growth impairment, bone disease, surgery, response to therapy and disease extension. Study selection was performed by two reviewers. Risk of bias was assessed with the Newcastle-Ottawa tool. Results: The search identified 97 eligible studies (all observational). The majority focused on associations with surgery (n = 46), internal stricturing (B2) (n = 32) or penetrating (B3) (n = 30) complications; fewer on growth impairment (n = 20) or perianal fistulising disease (n = 19); and very few on chronically active inflammatory disease (n = 9) or bone disease (n = 10). In a large (n = 913) prospective study, older age and non-Caucasian ethnicity were associated with adjusted hazard ratios (aHRs) of 1.4 (95% confidence interval (CI) 1.2-1.8) and 3.2 (1.4-7.3), respectively, for B3 complications. Across several studies, ASCA IgG was associated with aHRs of 2.7 to 2.8 for B3 disease and CBir1 with aHRs of 2.3 to 3.0 for B2 and/or B3 disease. In a single large study, the aHR of OmpC for B2 and/or B3 disease was 2.4 (1.2-4.9). Across several studies, male sex was associated with HRs of 3.6 to 3.9 for linear growth impairment. Lower weight and BMI, and more active disease were associated with lower bone mineral density over time. Table 1 lists factors for which at least one study reported an association with an outcome of interest. The number of studies demonstrating a positive association, amongst all studies examining the predictor, is shown in brackets. No clear risk factors were identified for chronically active inflammatory disease.
Conclusions:
The majority of identified predictors are observed demographic or phenotypic associations. To date, only antimicrobial serology provides additional guidance for individualising treatment based on risk prediction. Molecular predictors of chronically active inflammatory disease and biologic treatment responsiveness are badly needed.
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Risk of colorectal neoplasia, colectomy and responsiveness to biologic therapy in patients with inflammatory bowel disease and concomitant primary sclerosing cholangitis: A systematic review K. Wu, A. Thompson, N. Sheng Ding* St Vincent's Hospital Melbourne, Gastroenterology, Fitzroy, Australia Background: Primary sclerosing cholangitis (PSC) is a chronic immune-mediated liver disease commonly associated with inflammatory bowel disease (IBD) with the majority being diagnosed with ulcerative colitis (UC). Concomitant PSC with IBD can modify the Abstract P283 -Factors with at least 1 study demonstrating an association with an outcome of interest (numbers in brackets indicate the number of studies showing an association amongst all studies examining that factor).
Outcome
Demographic associations Phenotypic associations Serologic and genetic predictors Development of B2 disease L1 ± L4b disease (1/3 +) Antimicrobial serologies (1/2 +) Development of B3 disease Older age (2/4 +); non-Caucasian ethnicity (2/2 +) Antimicrobial serologies (2/3 +)
Development of B2 and/or B3 disease
Non-Caucasian ethnicity (1/1 +) L1 ± L4b disease (1/4 +) Antimicrobial serologies (3/3 +)
Intestinal resection
Older age (5/13 +); growth impairment at diagnosis (3/5 +) B2 ± B3 disease (5/6 +); L1 disease (2/11 +); colonic disease (2/11 -) Perianal fistulising disease Older age (2/3 +); non-Caucasian ethnicity (2/2 +) Linear growth impairment Male sex (4/9 +); younger age (4/8 +); diagnostic delay (2/4 +) L1 ± L4b disease (3/7 +)
